Dr Reddy's Infuses Life Into XenoPort's Psoriasis Drug
This article was originally published in Scrip
Executive Summary
Dr Reddy's Laboratories will take XenoPort's clinical-stage oral psoriasis NCE, XP23829, further in the US, infusing new hope in the prodrug of monomethyl fumarate (MMF) that has seen some safety issues in earlier studies and faces significant competition in the space.
You may also be interested in...
Psoriasis Sprays: Niche Opportunities?
Expanding treatment options for psoriasis highlight how some firms are developing innovative "lower risk" assets that use established active ingredients but could provide benefits to specific patient segments.
Arbor's Bid For XenoPort Likely Driven By Effort To Grow Horizant
With minimal unencumbered pipeline assets to offer, XenoPort's value to Arbor apparently lies in positive sales trends for the modest-selling restless legs and postherpetic neuralgia drug.
How Sanofi Is ‘Playing To Win’ In India, Watch Diabetes Space
Sanofi India managing director Rodolfo Hrosz talks to Scrip about the company’s refreshed India strategy including in the competitive diabetes segment, which is expected to see a flurry of new product activity. While Soliqua has hit the market, all eyes are also on Novo Nordisk’s Awiqli and Cipla’s partnered inhaled insulin in the wings.